Stem cell research and development underway at ViaCyte is seeking to change the way type 1 diabetes (T1D) is treated. This video explains how our stem cell research and development, funded by California’s Proposition 71: the California Stem Cell Research and Cures Initiative, is leading to potentially groundbreaking advances in treating diabetes. The video provides an informative and engaging overview on the cause of T1D, the inherent issues with current diabetes treatments, and how ViaCyte’s VC-01TM product candidate is working towards eliminating or reducing daily insulin injections. The VC-01 product candidate is designed to deliver an entire community of human hormone producing cells – including insulin producing beta cells – that are naturally found in the Islet of Langerhans to patients with T1D. This community of cells may act similarly to a normal healthy pancreas and could provide effective control of blood glucose levels thus providing a functional cure for the disease. ViaCyte has received funding and support from the California Institute for Regenerative Medicine (CIRM) and JDRF.
This video was produced as part of the Americans for Cures Foundation’s Report Back to the Public program. For more information about type 1 diabetes, check out the new Americans for Cures website, and follow Americans for Cures on Facebook and Twitter for live updates.